Tasigna Gains Expanded Indication for Rare Pediatric Leukemia

By March 22, 2018

The expanded approval was supported by 2 studies evaluating the safety and efficacy of Tasigna in 69 pediatric patients aged 2 to <18 years with Ph+ CML-CP who were either newly diagnosed (first-line) or who were resistant or intolerant to prior tyrosine kinase inhibitor (TKI) therapy (second-line).

USPSTF: Behavioral interventions do not reduce sunburn or skin cancer outcomes

March 22, 2018

Behavioral interventions increase sun protection behavior but do not reduce sunburn or skin cancer outcomes.

Links Between Hydrochlorothiazide and Non-Melanoma Skin CA Examined

March 22, 2018

High use of hydrochlorothiazide (≥50,000mg) was associated with basal cell carcinoma and squamous cell carcinoma.

Long-Term Effects of Eradicating <i>H. Pylori</i> Examined for Gastric Cancer Risk

March 22, 2018

For the 327 patients who underwent histologic analysis, improvement in the atrophy grade at the gastric corpus lesser curvature from baseline was observed in 48.4% of the patients in the treatment group and in 15% of those in the placebo group.

FDA Fast Tracks Pedmark for Prevention of Cisplatin-Induced Ototoxicity

By March 21, 2018

The Clinical Oncology Group Protocol ACCL0431 trial enrolled 125 pediatric patients newly diagnosed with a germ cell tumor, hepatoblastoma, medulloblastoma, neuroblastoma, osteosarcoma, or other malignancy.

USPSTF: Fair-Skin Youths Should be Counselled on Minimizing UV Exposure

March 21, 2018

Based on these findings, in order to reduce the risk of skin cancer, the USPSTF recommends counseling regarding minimizing exposure to ultraviolet radiation for those aged 6 months to 24 years with fair skin types (B recommendation).

Adcetris + Chemo OK'd as Frontline Tx for Advanced Classical Hodgkin Lymphoma

By March 20, 2018

FDA approval was based on positive results from the Phase 3 ECHELON-1 trial.

Can Radiation Dose-Escalation Up Survival in Prostate CA?

March 16, 2018

The 8-year rates of OS were 76 and 75% with 79.2 and 70.2 Gy, respectively (hazard ratio, 1.00; 95% confidence interval, 0.83 to 1.20; P=0.98). The 8-year cumulative rates of distant metastases were 4 and 6% for the 79.2- and 70.2-Gy arms, respectively (hazard ratio, 0.65; 95% confidence interval, 0.42 to 1.01; P=0.05).

Incidence of Breast Cancer Investigated Among Women With Schizophrenia

March 16, 2018

The researchers included 12 cohorts (760 women) in this meta-analysis. Pooled analysis showed that schizophrenia was associated with a significantly increased risk of breast cancer incidence in women (SIR, 1.31; P<0.001).

High Prevalence of Sunburn in U.S. Highlights Need for Targeted Prevention

March 15, 2018

The researchers found that 34.2% of participants experienced sunburn in 2015. The prevalence was higher among younger age groups (51.2% for those aged 18 to 29 years) and in non-Hispanic whites and those with sun-sensitive skin (42.5 and 50.2%, respectively).

Cabometyx sNDA for Hepatocellular Carcinoma Indication Submitted to FDA

By March 15, 2018

CELESTIAL is a randomized, double-blind, placebo-controlled study of cabozantinib in patients with advanced HCC conducted at more than 100 sites globally in 19 countries.

Colonoscopy significantly reduces mortality from colorectal cancer in Veterans Affairs study

March 14, 2018

Colonoscopy in veterans was associated with reduced mortality from both left and right-sided colorectal cancer.

iPad app that allows patients to order tests doubles colon cancer screening rates in study

March 13, 2018

Digital health intervention resulted in significantly higher colon cancer screening rates among participants.

Pre-Diagnostic Circulating Vit D Concentration and Cancer Risk: Is There a Link?

March 13, 2018

The researchers found that there was an inverse correlation for plasma 25-hydroxyvitamin D concentration with the risk of total cancer, with multivariable adjusted hazard ratios of 0.81 (95% confidence interval [CI], 0.7 to 0.94), 0.75 (95% CI, 0.65 to 0.87), and 0.78 (95% CI, 0.67 to 0.91) for the second to fourth quarters versus the lowest quarter, respectively (P=0.001).

Opioid Rx Patterns Examined for Head and Neck, Lung and Colon Cancer

March 12, 2018

The researchers identified 168 prescriptions associated with HNCA and 571 with LCCA diagnoses. Compared to patients with LCCA, patients with HNCA had significantly increased odds of being prescribed an opioid (odds ratio, 1.68).

Use of Carvedilol for Anthracycline Cardiotoxicity Prevention Investigated

March 12, 2018

Carvedilol does not prevent reduction in LVEF in breast cancer but is linked to lower troponin I levels

NCCN Frequently Makes Recommendations Beyond FDA-Approved Drug Indications

March 12, 2018

The researchers found that the 47 drugs were authorized for 69 FDA-approved indications. The NCCN, however, recommended these drugs for 113 indications, of which 62% overlapped with FDA-approved indications, and 39% were additional recommendations.

FDA Approves New Dosing Option for Opdivo

By March 06, 2018

This approval will provide healthcare professionals the flexibility to customize patient care.

FDA Authorizes First Direct-to-Consumer BRCA Mutation Test

By March 06, 2018

According to a National Cancer Institute study about 2% of Ashkenazi Jewish women carry 1 of the hereditary mutations the test can detect. Among other ethnic populations this occurrence is only 0% to 0.1%.

New Scale May Help Identify Patients Addicted to Tanning

March 05, 2018

The researchers found that tanning addiction was positively associated with being female, not being in a relationship, extroversion, neuroticism, anxiety, and obsessive-compulsiveness. New Screening Tool Developed to Assess Tanning Addiction

Calcium, Vit. D Supplementation Linked to Increased Risk of Serrated Polyps

March 02, 2018

Late effect findings of sessile serrated adenomas, polyps in those taking calcium with/without vitamin D

First-in-Class Pancreatic Cancer Candidate Gets Fast Track Status

By March 01, 2018

Pamrevlumab is a first-in-class antibody developed by FibroGen to inhibit the activity of connective tissue growth factor.

The Skin Bacteria That Could Inhibit Melanoma Growth

March 01, 2018

Compared with mice colonized with a control S. epidermidis strain that did not produce 6-HAP, colonization of mice with a 6-HAP-producing strain reduced the incidence of ultraviolet-induced tumors. Multiple healthy human subjects had S. epidermidis strains producing 6-HAP.

Lower Cancer Recurrence May Be Linked to Higher Nut Intake

March 01, 2018

After a median follow-up of 6.5 years, the researchers found that individuals who consumed 2 or more servings of nuts per week had adjusted hazard ratios of 0.58 for disease-free survival and 0.43 for overall survival.

Verzenio Gains Expanded Breast Cancer Indication

By February 27, 2018

The approval of Verzenio as initial therapy in combination with an aromatase inhibitor is based on the efficacy and safety demonstrated in the pivotal MONARCH 3 clinical trial.

Metformin, Statin Use and Ovarian Cancer Risk: What's the Link?

February 27, 2018

The researchers found that 303 women were diagnosed with ovarian cancer during the follow-up period. Metformin was not associated with the incidence of ovarian cancer (hazard ratio, 1.02) compared to other oral antidiabetic medications.

Treatment-Free Remission Assessed After Nilotinib Discontinuation in CML

February 26, 2018

A total of 163 patients who had switched from imatinib to nilotinib were enrolled in the study and entered the consolidation phase; 126 of these patients met the criteria for entering the TFR phase.

Dermoscopic Criteria Accuracy Assessed in Diagnosing Melanoma in Situ

February 23, 2018

The researchers found that 25.3% of the lesions were MIS. The most frequent dermoscopic criteria for MIS were regression, atypical network, and irregular dots and/or globules (92.9, 85.5, and 50.2%, respectively).

Kurtosis Diffusion-Weighted Imaging May Reduce False Positive Mammographies

February 23, 2018

At the predefined sensitivity of greater than 98.0%, the researchers found that the radiomics feature model reduced false-positive results from 66 to 20 in the independent test set (specificity, 70.0%); BI-RADS 4a and 4b lesions benefited from the analysis (74.0 and 60.0%, respectively).

Obese Individuals May Have Greater Metastatic Melanoma Survival Odds

February 21, 2018

The obesity-related survival benefit was seen only for patients receiving targeted therapy (hazard ratios, 0.72 and 0.6 for progression-free and overall survival, respectively) and immunotherapy (hazard ratios, 0.75 and 0.64, respectively), not for patients receiving chemotherapy.